S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Jain, Tania, Otoukesh, Salman, Gerds, Aaron T., Lucchesi, Alessandro, Romina Sosa, Iberia, Laribi, Kamel, Mishchenko, Elena, Radinoff, Atanas, Benevolo, Giulia, Vannucchi, Alessandro M., Boyer, Francoise, Quittet, Philippe, Radsak, Markus, Machet, Antoine, Bose, Prithviraj, Huang, Zhuying, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428378/
http://dx.doi.org/10.1097/01.HS9.0000967752.72578.ff
_version_ 1785090454659792896
author Mascarenhas, John
Jain, Tania
Otoukesh, Salman
Gerds, Aaron T.
Lucchesi, Alessandro
Romina Sosa, Iberia
Laribi, Kamel
Mishchenko, Elena
Radinoff, Atanas
Benevolo, Giulia
Vannucchi, Alessandro M.
Boyer, Francoise
Quittet, Philippe
Radsak, Markus
Machet, Antoine
Bose, Prithviraj
Huang, Zhuying
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Passamonti, Francesco
author_facet Mascarenhas, John
Jain, Tania
Otoukesh, Salman
Gerds, Aaron T.
Lucchesi, Alessandro
Romina Sosa, Iberia
Laribi, Kamel
Mishchenko, Elena
Radinoff, Atanas
Benevolo, Giulia
Vannucchi, Alessandro M.
Boyer, Francoise
Quittet, Philippe
Radsak, Markus
Machet, Antoine
Bose, Prithviraj
Huang, Zhuying
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Passamonti, Francesco
author_sort Mascarenhas, John
collection PubMed
description
format Online
Article
Text
id pubmed-10428378
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104283782023-08-17 S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX Mascarenhas, John Jain, Tania Otoukesh, Salman Gerds, Aaron T. Lucchesi, Alessandro Romina Sosa, Iberia Laribi, Kamel Mishchenko, Elena Radinoff, Atanas Benevolo, Giulia Vannucchi, Alessandro M. Boyer, Francoise Quittet, Philippe Radsak, Markus Machet, Antoine Bose, Prithviraj Huang, Zhuying Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Passamonti, Francesco Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428378/ http://dx.doi.org/10.1097/01.HS9.0000967752.72578.ff Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Mascarenhas, John
Jain, Tania
Otoukesh, Salman
Gerds, Aaron T.
Lucchesi, Alessandro
Romina Sosa, Iberia
Laribi, Kamel
Mishchenko, Elena
Radinoff, Atanas
Benevolo, Giulia
Vannucchi, Alessandro M.
Boyer, Francoise
Quittet, Philippe
Radsak, Markus
Machet, Antoine
Bose, Prithviraj
Huang, Zhuying
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Passamonti, Francesco
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title_full S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title_fullStr S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title_full_unstemmed S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title_short S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
title_sort s210: an open-label, global, phase (ph) 1b/2 study adding navtemadlin (nvtm) to ruxolitinib (rux) in patients (pts) with primary or secondary myelofibrosis (mf) who have a suboptimal response to rux
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428378/
http://dx.doi.org/10.1097/01.HS9.0000967752.72578.ff
work_keys_str_mv AT mascarenhasjohn s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT jaintania s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT otoukeshsalman s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT gerdsaaront s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT lucchesialessandro s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT rominasosaiberia s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT laribikamel s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT mishchenkoelena s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT radinoffatanas s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT benevologiulia s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT vannucchialessandrom s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT boyerfrancoise s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT quittetphilippe s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT radsakmarkus s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT machetantoine s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT boseprithviraj s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT huangzhuying s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT qamooshope s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT mcgreivyjesse s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT rothbaumwaynep s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT verstovseksrdan s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux
AT passamontifrancesco s210anopenlabelglobalphaseph1b2studyaddingnavtemadlinnvtmtoruxolitinibruxinpatientsptswithprimaryorsecondarymyelofibrosismfwhohaveasuboptimalresponsetorux

Ejemplares similares